Antimicrobial

Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan…

11 months ago

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Revenues increased 7% compared to quarter from prior year and 15% from prior quarterImprovement in gross margin for quarter of…

11 months ago

Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray

Kane will introduce its unique spray gel at the Boswick Burn and Wound Care SymposiumWINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE…

11 months ago

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both…

11 months ago

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

11 months ago

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY has received a Prescription Drug User Fee Act (PDUFA) target action date of April 24, 2024FDA granted Qualified Infectious…

11 months ago

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals,…

12 months ago

CorMedix Inc. Announces Commercial and Operational Updates

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

12 months ago

Basilea provides portfolio status update

Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024Cresemba in-market sales…

12 months ago

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…

12 months ago